PSC
BMRN icon

Piper Sandler & Co’s BioMarin Pharmaceuticals BMRN Stock Holding History

Piper Sandler & Co’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,385
Closed -$145K – 20
2015
Q4 		$145K Buy
+1,385
New +$145K 0.37% 16

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Piper Sandler & Co's BMRN Position: Q1 2016 in Review

Piper Sandler & Co sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2016, closing a stake of 1,385 shares — an estimated $145K sold.

Piper Sandler & Co first reported a position in BMRN in Q4 2015 and held it in 1 quarter. The position peaked at $145K in Q4 2015. 390 funds tracked by Wall St. Rank hold BMRN as of Q1 2016.

  • Piper Sandler & Co reported no remaining BioMarin Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Piper Sandler & Co sold 1,385 BioMarin Pharmaceuticals shares in Q1 2016, an estimated $145K.
  • Piper Sandler & Co first reported a position in BioMarin Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Piper Sandler & Co's BioMarin Pharmaceuticals position peaked at $145K in Q4 2015.
  • 390 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2016.

Based on Piper Sandler & Co's 13F filing for Q1 2016, filed 16 May 2016.